Palmer S, Di Bello S, Davenport S L, Herzig J W
Pharmaceuticals Division, Ciba-Geigy Limited, Basel, Switzerland.
Cardiovasc Res. 1996 Aug;32(2):411-21. doi: 10.1016/0008-6363(96)00098-3.
The aim was to determine whether, and by what mechanism(s), a novel inotropic agent 5-methyl-6-phenyl-1,3,5,6-tetrahydro-3, 6-methano-1,5-benzodiazocine-2,4-dione (BA 41899) and its enantiomers directly alter the Ca2+ sensitivity of cardiac myofilaments.
Porcine ventricular trabeculae were permeabilised with Triton X-100. The relationship between force and pCa (-log[Ca2+]) was determined in the presence and absence of ATP. Troponin I was extracted, using vanadate, to produce unregulated maximally activated myofilaments. Force and actomyosin ATPase activity were measured simultaneously to determine tension cost (ATPase activity/tension). The effects of the (+) enantiomer (CGP 48506) on the twitch of intact muscle were demonstrated using rat papillary muscle.
100 microM BA 41899 had a pronounced Ca2+ sensitising effect on force production by porcine skinned cardiac fibres, increasing the pCa required for 50% maximal activation by 0.64 units, while suppressing maximum force by 18.3%. Resting tension was unaffected. These actions were primarily caused by CGP 48506 and were concentration dependent. At concentrations less than 100 microM, CGP 48506 also increased twitch amplitude in intact papillary muscles with no effect on resting tension, whereas 100 microM CGP 48506 increased resting force due to a slowing of relaxation. 100 microM CGP 48506 potentiated Ca(2+)-independent rigor tension in skinned trabeculae, indicating a Ca2+ sensitising mechanism unrelated to Ca2+ binding to troponin C. Tension cost was unaffected by 100 microM CGP 48506 over the entire range of activating Ca2+ concentrations. Suppression of maximum force by CGP 48506 was independent of both Ca2+ concentration and the regulatory troponin complex.
Both the increase in Ca2+ sensitivity during submaximal activation and the depression of maximum force which are induced by CGP 48506 in skinned trabeculae occur at least partly through Ca(2+)-independent mechanisms.
旨在确定一种新型正性肌力药物5-甲基-6-苯基-1,3,5,6-四氢-3,6-亚甲基-1,5-苯并二氮杂䓬-2,4-二酮(BA 41899)及其对映体是否以及通过何种机制直接改变心肌肌丝的Ca2+敏感性。
用Triton X-100使猪心室小梁透化。在有和没有ATP的情况下测定力与pCa(-log[Ca2+])之间的关系。使用钒酸盐提取肌钙蛋白I,以产生无调节的最大激活肌丝。同时测量力和肌动球蛋白ATP酶活性以确定张力消耗(ATP酶活性/张力)。使用大鼠乳头肌证明(+)对映体(CGP 48506)对完整肌肉收缩的影响。
100μM BA 41899对猪去表皮心脏纤维产生的力有明显的Ca2+增敏作用,使50%最大激活所需的pCa增加0.64个单位,同时使最大力降低18.3%。静息张力不受影响。这些作用主要由CGP 48506引起,且呈浓度依赖性。在浓度低于100μM时,CGP 48506还增加了完整乳头肌的收缩幅度,对静息张力无影响,而100μM CGP 48506由于舒张减慢而增加了静息力。100μM CGP 48506增强了去表皮小梁中与Ca2+无关的强直张力,表明存在一种与Ca2+结合到肌钙蛋白C无关的Ca2+增敏机制。在整个激活Ca2+浓度范围内,100μM CGP 48506对张力消耗无影响。CGP 48506对最大力的抑制与Ca2+浓度和调节性肌钙蛋白复合物均无关。
CGP 48506在去表皮小梁中诱导的次最大激活期间Ca2+敏感性增加和最大力降低至少部分是通过与Ca2+无关的机制发生的。